The SM Journey: Sharing
Explore insights and strategies for managing the disease long-term.
-
-
HT-KIT receives FDA Orphan Drug Designation for SM
-
FDA grants Breakthrough Designation to bezuclastinib for nonadvanced SM
-
My 2-year journey to getting disability for indolent SM
-
SM without skin involvement may mean higher anaphylaxis risk
-
How does systemic mastocytosis impact the brain?
-
The gut microbiome may influence symptoms and disease activity in SM
